Loading clinical trials...
Loading clinical trials...
A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult Subjects
Conditions
Interventions
Epetraborole and matching placebo
Epetraborole
+2 more
Locations
1
United States
423001
Tempe, Arizona, United States
Start Date
June 5, 2023
Primary Completion Date
July 26, 2023
Completion Date
August 3, 2023
Last Updated
December 21, 2023
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
AN2 Therapeutics, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions